Slide 1: Exchange filing cover letter for Q2 FY24 Investor Presentation
15th November 2023 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam, Sub: - Q2 FY24
Slide 2: Natco Pharma Limited Investor Presentation Q2FY24
NATCO PHARMA LIMITED INVESTOR PRESENTATION Q2FY24 1
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Key Highlights
KEY HIGHLIGHTS Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW Strong brand position in domestic pharma segments • Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer • Expan
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Financial Performance(1) (₹ million) Profitability Margins 28,117 43.2% 41.6% 22,424 22,247 21,557 20,224 20,438 37.0% 34.1% 32.9% 31.0% 29.0% 25.4% 22.8% 20.5% 9,688 10,402 17.7% 9,250 6,962 6,444 6,900 7,098 7,153 4,608 4,409 3,625 8.3% 1,700 FY18 FY19 FY20 FY21 FY22 FY23 F
Slide 6: Key Business Segments
KEY BUSINESS SEGMENTS DOMESTIC FORMULATIONS EXPORT FORMULATIONS SUBSIDIARIES API BUSINESS • Three key business segments: Oncology, • Focused on niche opportunities in the • Operations in Brazil, Canada, • 45 active DMFs(2) in the US with niche Specialty Pharma, Cardiology and US, Canada and emerging
Slide 7: US Market Focus - Complex Generics & Frontend
US MARKET FOCUS- COMPLEX GENERICS & FRONTEND KEY PRODUCTS IN THE PORTFOLIO (1) Therapeutic Segment Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the Key Brand Molecule following: / Primary Indication ▪ Intricate Chemistry Revlimid
Slide 8: Resilient Domestic Pharma Business
RESILIENT DOMESTIC PHARMA BUSINESS OVERVIEW OF DOMESTIC PHARMA BUSINESS ONCOLOGY Three key business segments: Oncology, Pharma specialty and Cardiology & Diabetology One of the leaders in the branded oncology medicines in India Two decades of strong presence in oncology segment with 54(1) in Focus
Slide 9: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA Strong portfolio with 30+ products including Oncology, anti-viral, cardiovascular and CNS therapies Amongst top 10 generic companies by sales revenue in Canada 25 approvals in place Highest market share of Nat-Lenalidomide in this molecule Launched Nat-Pomalidomide, Nat
Slide 10: API Facilities
API FACILITES Strategically important business – develops APIs primarily for third party sales and also for captive consumption MEKAGUDA TELANGANA Portfolio of 45 (1) active US DMFs with niche products under development Oncology API's and speciality products Focus on complex oncology molecules. Othe
Slide 11: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS DOMESTIC MARKETS KOTHUR VISAKAPATNAM NAGARJUNASAGAR GUWAHATI DEHRADUN TELANGANA ANDHRA PRADESH TELANGANA ASSAM UTTARAKHAND Oral and solid dosages including Solid oral tablet and capsule Oncology, Antibiotics and Tablets, Capsules Tablets, Capsules dry pow
Slide 12: R&D Capabilities
R&D CAPABILITIES R&D Expense (₹ in million) 2,500 12% 14.0% R&D capabilities demonstrated by its complex and niche product filings in 12.0% formulations and API segments 2,000 9.3% 9.1% 8.7% 10.0% 8% 1,500 7.8% 8.0% 2,267 6.0% Two research facilities with capabilities across synthetic chemistry, nan
Slide 13: Crop Health Sciences
CROP HEALTH SCIENCES Leveraging strong Techno-Legal expertise in Pharma to drive business in Agro-Chemical segment. Manufacturing Facilities include a Technical (Active Ingredient) and Formulation asset, located in the state of Andhra Pradesh. Operate additional leased facilities, especially to supp
Slide 14: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (INR Million) Revenue Division Q2FY24 Q1FY24 Q2FY23 FY23 FY22 A) API Revenue 778 751 441 2,103 2,481 B) Formulation B1) Formulation – Exports (incl profit share, license income, 7,923 8,842 2,834 20,632 11,842 export service income & Subsidiaries) B2)
Slide 15: Consolidated Profit & Loss Statement (as reported)
CONSOLIDATED PROFIT & LOSS STATEMENT (as reported) Profit & Loss Statement (INR Million) Q2FY24 Q1FY24 Q2FY23 FY23 FY22 Total Revenue 10,608 11,602 4,526 28,117 20,438 Gross Profit 8,450 9,642 3,468 21,844 14,829 Gross Margin (%)* 79.7% 83.1% 76.6% 77.7% 72.6% Overheads 3,576 4,165 2,310 11,442 11,2
Slide 16: Consolidated Balance Sheet (as reported)
CONSOLIDATED BALANCE SHEET (as reported) Balance Sheet (INR Million) As of September 2023 As of March 2023 Assets Net tangible assets 23,531 23,034 Goodwill and other intangibles 1,984 1,878 Financial assets 2,550 1,043 Deferred tax asset (net) 152 0 Other non-current assets 481 271 Other non-curren
Slide 17: Thank You
Contact Us Thank You For any queries, please contact Rajeev Menon, Investor Relations r.menon@natcopharma.co.in Rajesh Chebiyam, Executive Vice President, Crop Health Sciences ir@natcopharma.co.in Phone: 040-2354 7532 16